 |
|
Recent updates on systemic treatment of atopic dermatitis
Jiyoung Ahn
Clin Exp Pediatr. 2024;67(11):580-588. Published online 2024 Nov 1 DOI: https://doi.org/10.3345/cep.2024.00339
|
|
Citations to this article as recorded by
 Severe psoriasis relapse following tralokinumab therapy for atopic dermatitis
Nikkia Zarabian, Mina Farah, Joseph Zahn, Adam Friedman
JAAD Case Reports.2026;[Epub] CrossRef OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet
Journal of the European Academy of Dermatology and.2026;[Epub] CrossRef Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son
JEADV Clinical Practice.2026; 5(2): 529. CrossRef Vitamin D and Atopic Dermatitis—A Mere Correlation or a Real Supportive Treatment Option?
Kamil Przechowski, Marta Natalia Krawczyk, Rafał Krasowski, Rafał Pawliczak, Paulina Kleniewska
Nutrients.2025; 17(16): 2582. CrossRef Chemical Characterization of the Traditional Chinese Medicine Zishui Qingxin Yin by Ultra‐High Performance Liquid Chromatography and Q Exactive Orbitrap Mass Spectrometers Combined With Molecular Networking and Quantitative Analysis of the Main Components
Fei Pang, Yi‐Wei Zhou, Ying‐Chu Shi, Yu‐Xin Yu, Jiu‐Xia Gao, Ling Zhang, Jia Xu
Journal of Separation Science.2025;[Epub] CrossRef
|